Envista (NYSE:NVST) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Envista (NYSE:NVST) from a buy rating to a strong-buy rating in a research report released on Monday morning.

Other equities analysts also recently issued research reports about the company. Robert W. Baird set a $27.00 price target on Envista in a research report on Friday, October 31st. Evercore ISI reiterated an “outperform” rating on shares of Envista in a research note on Friday, October 31st. Barclays initiated coverage on Envista in a research note on Monday, December 8th. They issued an “overweight” rating and a $24.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Envista in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Envista from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, December 16th. Five equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Envista has a consensus rating of “Hold” and a consensus target price of $22.17.

Envista Price Performance

Shares of NVST opened at $24.05 on Monday. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 0.47. The company’s fifty day simple moving average is $22.04 and its 200 day simple moving average is $20.96. Envista has a 1-year low of $14.22 and a 1-year high of $25.41. The company has a market cap of $3.95 billion, a price-to-earnings ratio of 267.27, a PEG ratio of 1.06 and a beta of 0.99.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $669.90 million during the quarter, compared to analysts’ expectations of $639.49 million. Envista had a net margin of 0.58% and a return on equity of 5.90%. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.12 earnings per share. On average, research analysts forecast that Envista will post 1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

A number of hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC raised its stake in Envista by 317.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after purchasing an additional 1,026 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after purchasing an additional 1,504 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after purchasing an additional 949 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Envista by 378.0% in the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock valued at $47,000 after buying an additional 1,909 shares in the last quarter. Finally, SJS Investment Consulting Inc. boosted its stake in shares of Envista by 10,356.5% in the third quarter. SJS Investment Consulting Inc. now owns 2,405 shares of the company’s stock valued at $49,000 after buying an additional 2,382 shares during the period.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.